Iovance Biotherapeutics to Present at Upcoming Conferences in December
November 30 2020 - 7:21AM
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage
biotechnology company developing novel T cell-based cancer
immunotherapies, today announced that the company plans to present
at the following conferences in November:
- Piper Sandler 32nd Annual Virtual Healthcare
Conference | December 1-3,
2020Date/Time: presentation available at
http://ir.iovance.com
- Cellular Immunotherapies for Solid Tumors
Summit | December 1-3,
2020Presentation Title: Clinical Success of TIL Technology
Platform in Multiple Solid TumorsDate/Time: Thursday, Dec. 3 at
2:10 pm ET at www.solid-tumors-summit.com
Live and archived webcasts of investor conference presentations
will be available in the Investors section of the Iovance website
at http://ir.iovance.com.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics aims to improve patient care by making T
cell-based immunotherapies broadly accessible for the treatment of
patients with solid tumors and blood cancers. Tumor infiltrating
lymphocyte (TIL) therapy uses a patient’s own immune cells to
attack cancer. TIL cells are extracted from a patient’s own tumor
tissue, expanded through a proprietary process, and infused back
into the patient. Upon infusion, TIL reach tumor tissue, where they
attack cancer cells. The company has completed dosing in the
pivotal study in patients with metastatic melanoma and cervical
cancer. In addition, the company’s TIL therapy is being
investigated for the treatment of patients with locally advanced,
recurrent or metastatic cancers including head and neck and
non-small cell lung cancer. A clinical study to investigate Iovance
T cell therapy for blood cancers called peripheral blood lymphocyte
(PBL) therapy is open to enrollment. For more information, please
visit www.iovance.com.
Forward-Looking Statements
Certain matters discussed in this press release are
“forward-looking statements” of Iovance Biotherapeutics, Inc.
(hereinafter referred to as the “Company,” “we,” “us,” or “our”)
within the meaning of the Private Securities Litigation Reform Act
of 1995 (the “PSLRA”). All such written or oral statements made in
this press release, filings with the Securities and Exchange
Commission (“SEC”), reports to stockholders and in meetings with
investors and analysts, other than statements of historical fact,
are forward-looking statements and are intended to be covered by
the safe harbor for forward-looking statements provided by the
PSLRA. Without limiting the foregoing, we may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,”
“forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes and are intended to identify forward-looking statements.
These forward-looking statements include, but are not limited to,
statements regarding the success, timing, projected enrollment,
manufacturing and production capabilities, and cost of our ongoing
clinical trials and anticipated clinical trials for our current
product candidates (including both Company-sponsored and
collaborator-sponsored trials in both the U.S. and Europe), such as
statements regarding the timing of initiation and completion of
these trials; the strength of the Company’s product pipeline; and
the guidance provided for the Company’s future cash, cash
equivalents, short term investments, restricted cash balances, and
forecasted operating expenses. These statements involve risks,
uncertainties and other factors that may cause actual results,
levels of activity, performance, achievements and developments to
be materially different from those expressed in or implied by these
forward-looking statements, including, without limitation, the
following substantial known and unknown risks and uncertainties
inherent in the Company’s business: the COVID-19 pandemic may have
an adverse effect on the Company and its clinical trials, including
potential slower patient recruitment, inability of clinical trial
sites to collect data, inability of the Company or its contract
research organizations to monitor patients, as well as U.S. Food
and Drug Administration (“FDA”) availability due to competing
priorities; our ability to achieve long-term profitability and
successfully commercialize our products alone or with third
parties, as well as our history of operating losses and our
expectations that we will continue to incur significant operating
losses; our limited operating history in our current line of
business, which makes it difficult to evaluate our prospects, our
business plan or the likelihood of our successfully implementing
such business plan; risks related to the timing of and our ability
to successfully develop, submit, obtain and maintain FDA or other
regulatory authority approval of, or other action with respect to,
our product candidates (including, with respect to lifileucel for
the treatment of metastatic melanoma, reaching agreement with the
FDA on the appropriate potency assay and the timing to submit a
biologics licensing application (“BLA”) to the FDA), and our
ability to successfully commercialize any product candidates for
which we obtain FDA approval; our limited history in conducting
clinical trials, on which our future profitability is substantially
dependent, and our need to rely on third parties, including
contract research organizations, contract manufacturing
organizations and consultants, in connection with the conduct,
supervision and monitoring of our clinical trials for our product
candidates; preliminary and interim clinical results, which may
include efficacy and safety results, from ongoing Phase 2 studies
may not be reflected in the final analyses of our ongoing clinical
trials or subgroups within these trials; the risk that a slower
rate of enrollment may delay the Company’s clinical trial timelines
or otherwise adversely impact our clinical development activities;
the risk that enrollment may need to be adjusted for the Company’s
trials and cohorts within those trials based on FDA and other
regulatory agency input; the new version of the protocol which
further defines the patient population to include more advanced
patients in the Company’s cervical cancer trial may have an adverse
effect on the results reported to date; the risk that the results
obtained in our ongoing clinical trials may not be indicative of
results obtained in future clinical trials or that data within
these trials may not be supportive of product approval, including
that later developments with the FDA may be inconsistent with
already completed FDA meetings; the risk that the FDA may not agree
with our approach to expand our cervical cancer trial to include
Cohort 2 of the C-145-04 trial; the risk that changes in patient
populations may result in changes in preliminary clinical results;
the Company’s ability or inability to address FDA or other
regulatory authority requirements relating to its clinical programs
and registrational plans, such requirements including, but not
limited to, clinical, safety, manufacturing and control
requirements; the risk that regulatory authorities may potentially
delay the timing of FDA or other regulatory approval of, or other
action with respect to, our product candidates, or that we may be
required to conduct additional clinical trials or modify ongoing or
future clinical trials based on feedback from the FDA or other
regulatory authorities; the risk that the Company’s interpretation
of the results of its clinical trials or communications with the
FDA may differ from the interpretation of such results or
communications by the FDA; our ability to obtain and maintain
intellectual property rights related to our product pipeline; our
ability to successfully implement our research and development
programs and collaborations; the acceptance by the market of our
product candidates and their potential reimbursement by payors, if
approved; our ability to obtain tax incentives and credits and the
risk that our existing net operating loss carryforwards and
research tax credits may expire or otherwise be limited in use; the
success of our manufacturing, license or development agreements;
risks related to the Company’s ability to maintain and benefit from
accelerated FDA review designations, including breakthrough therapy
designation or regenerative medicine advanced therapy designation,
which may not result in a faster development process or review of
the Company’s product candidates (and which may later be rescinded
by the FDA), and which does not assure approval of such product
candidates by the FDA or the ability of the Company to obtain FDA
approval in time to benefit from commercial opportunities; the
ability or inability of the Company to manufacture its therapies
using third party manufacturers or its own facility may adversely
affect the Company’s potential commercial launch; the results of
clinical trials with collaborators using different manufacturing
processes may not be reflected in the Company’s sponsored trials;
our dependence on additional financing to fund our operations and
complete the development and commercialization of our product
candidates, and the risks that raising such additional capital may
restrict our operations or require us to relinquish rights to our
technologies or product candidates; the risk that additional
expenses may decrease our estimated cash balances and increase our
estimated capital requirements; and other factors that may have a
material adverse effect on the Company’s business and clinical
development, including general economic conditions, the Covid-19
pandemic and regulatory developments, not within the Company’s
control.
CONTACTS
Iovance Biotherapeutics, Inc:Sara Pellegrino,
IRCVice President, Investor Relations & Public
Relations650-260-7120 ext. 264Sara.Pellegrino@iovance.com
Solebury Trout:Chad Rubin
(investors)646-378-2947crubin@troutgroup.com
Rich Allan (media)646-378-2958rallan@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Sep 2023 to Sep 2024